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CAcute graft-versus-host-disease (aGVHD) medi-
ted by donor T cells complicates 40%-70% of allo-
eneic transplants. The prognosis of steroid-refrac-
ory aGVHD [1] is poor, with suboptimal responses to
urrently available agents [2]. The role of B lympho-
ytes in the pathogenesis of GVHD is unclear, but
ecent reports of the successful use of rituximab in
hronic graft-versus-host disease (cGVHD) support
he hypothesis that a coordinated B and T cell re-
ponse is instrumental in cGVHD [3,4]. The signiﬁ-
ance of B cells in the pathogenesis of aGVHD is
nknown, but we report on 3 patients who received
ituximab, with complete improvement in aGVHD.
The ﬁrst patient was a 51-year-old woman who
eceived a matched unrelated peripheral blood stem
ell transplant for refractory diffuse large B cell lym-
homa. After engraftment on day 12, she developed
rade III aGVHD on day 25. On day 27, she
eveloped severe transplant-associated thrombotic
hrombocytopenic purpura (TTP) manifesting as sei-
ure, encephalopathy, brain edema, renal failure, fe-
er, and thrombocytopenia that failed to respond to
ethyl prednisone and 26 sessions of plasmapheresis.
ituximab was initiated for refractory TTP [5] on day
58 while plasma exchange was continued. After 3
oses of weekly rituximab, there was resolution of
TP. At the time of initiation of rituximab, the pa-
ient also had active grade III aGVHD (skin grade III,
iopsy-proved gut aGVHD grade III with2.0 L/day
f diarrhea) that was refractory to steroids. Decreased
VHD was noted from day 79 with complete res-
lution of aGVHD on day 95. During the course of
ituximab, steroids were progressively tapered. Be-
ond 100 days she had limited cGVHD involving the
kin that was well controlled on oral prednisone at 10
g/day and 100% donor chimerism.
Incidental improvement in aGVHD with ritux-mab prompted its use in 2 additional patients with HGVHD that was refractory to multiple immunosup-
ressants (Table 1). Complete resolution of aGVHD
ccurred on 16 and 15 days. These responses appeared
everal days after stopping previous inﬂiximab/dacli-
umab therapy, thus supporting the activity of ritux-
mab in aGVHD. Although long-term outcome is
nknown, observation of complete aGVHD responses
ith rituximab in 3 patients requires conﬁrmation in a
arger trial. The decrease in aGVHD after B cell
epletion is intriguing and raises questions concerning
ts pathogenic role.
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Table 1. Patient and Disease Characteristics of 3 Patients with Steroid-Refractory aGVHD
Patient
Age/Sex Diagnosis/Stage
Allogeneic
Transplant
GVHD
Prophylaxis
Organ Involved/
aGVHD Grade
Previous GVHD
Therapy
Timing/Doses
of Rituximab
Time to
Response aGVHD Response Outcome
51 F DLBCL Mel-Flu-Alem Tacrolimus Skin/III Steroids (6.4 g) Day 58/3 37 d Complete residual limited cGVHD Died of sepsis on day 160
MUD/PBSCT Gut/III
Grade III
39 F CML/BC CY/TBI Tacrolimus Skin/III Steroids (3.6 g) Day 61/2 16 d Complete resolution Alive in mCR
MRD/PBSCT MTX Liver/II Infliximab 6
Gut/III
Grade III
39 M AML/M-7 CY/TBI/Alem Tacrolimus Liver/II Steroids (7.2 g) Day 49/4 15 d Complete resolution Alive in CR
MUD/PBSCT Gut/IV Infliximab 5
Grade IV Daclizumab 4
GVHD indicates graft-versus-host disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; F, female; M, male; DLBCL, diffuse large B cell lymphoma;
Mel, melphalan; Flu, ﬂudarabine; Alem, alemtuzumab; MUD, matched unrelated donor; PBSCT, peripheral blood stem cell transplant; CML, chronic myeloid leukemia; BC, blast crisis;
CY, cyclophosphamide; TBI, total body irradiation; MRD, matched related transplant; MTX, methotrexate; CR, complete remission; mCR, molecular complete remission; M7, acute
megakaryoblastic leukemia.
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